Pomerantz Investigates Emergent BioSolutions Securities Claims
Analysis based on 12 articles · First reported Aug 25, 2026 · Last updated Sep 10, 2026
The investigation adds legal and reputational pressure on Emergent BioSolutions after its sharp guidance cut and impairment charge, keeping downside risk elevated for the stock. Broader market impact is limited, as the matter is company-specific and does not signal systemic issues for the pharmaceutical sector.
Pomerantz LLP LLP announced it is investigating claims on behalf of investors of Emergent BioSolutions Inc. concerning whether the company and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. The investigation follows Emergent's August 5, 2026 report of results for the quarter ended June 30, 2026, in which the company announced a $191.3 million non-cash impairment charge on the NARCAN asset group, driving a GAAP net loss of $180.2 million, and cut full year revenue guidance by approximately 10.8% at the midpoint. Management attributed the results to increased competitive intensity with implications for its near to medium term outlook and the book value of the NARCAN asset group. On this news, Emergent's stock price fell $2.23 per share, or 29.58%, to close at $5.31 per share on August 6, 2026. Pomerantz LLP, a firm known for securities class actions, is soliciting affected investors to contact it regarding potential claims. The investigation is at an early stage and no lawsuit has been filed.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard